 |
|
|
|
|
|
|
| Article 1 to 6 out of 6 concerning Celera Genomics
|
-
Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients
(25 Feb 2008)
Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland.The test, known as CRS7, ...
-
Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test
(24 Aug 2006)
Celera Genomics, an Applera Corporation business, announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza ...
-
Celera and Collaborators Discover Genetic Markers Associated with Early-onset Heart Attacks
(15 May 2006)
Celera Genomics, an Applera Corporation business, the University of California, San Francisco (UCSF), Cleveland Clinic, Case Western Reserve University and Brigham Young University, announced a publication describing two novel genetic markers ...
-
Applera and Beckman Coulter Announce Terms of Settlement of Legal Disputes regarding PCR technology
(28 Apr 2006)
Applera Corporation and Beckman Coulter, Inc. jointly announced that they have established the terms of a settlement to resolve all outstanding legal disputes between the parties regarding claims to certain Beckman Coulter patented capillary ...
-
Celera Genomics Acquires Full Ownership of Celera Diagnostics Joint Venture
(11 Jan 2006)
Celera Genomics to Partner or Sell Small Molecule Drug Development Programs
Applera Corporation announced that its Board of Directors has approved a restructuring of its Celera Diagnostics joint venture, whereby, effective January 1, 2006, Celera Genomics acquired Applied Biosystems' 50 percent interest in the joint venture ...
-
Celera Genomics and Abbott Announce Target Selection from Research Collaboration
(19 Apr 2005)
Celera Genomics Group, an Applera Corporation business, and Abbott announced that two Celera antigen targets have been selected for further investigation by Abbott for therapeutic development. These are the first targets to be selected for ...
|
|
|
|
|
Top
analytica
analytica China
analytica Vietnam
analytica Anacon